959709-11-6

Basic information

• Product Name: 2-bromo-4-methyl-thiazole-5-carboxylic acid benzylamide
• Synonyms: 2-bromo-4-methyl-thiazole-5-carboxylic acid benzylamide
• CAS NO: 959709-11-6
• Molecular Weight: 311.202
• Mol File: 959709-11-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-bromo-4-methyl-thiazole-5-carboxylic acid benzylamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-methyl-thiazole-5-carboxylic acid benzylamide(959709-11-6)
• EPA Substance Registry System: 2-bromo-4-methyl-thiazole-5-carboxylic acid benzylamide(959709-11-6)

Safety Data

• Hazardous Substances Data: 959709-11-6(Hazardous Substances Data)

Upstream product

• 40003-41-6 2-bromo-4-methyl-thiazole-5-carboxylic acid 
• 100-46-9 benzylamine 

Downstream Products

• 1009378-48-6 4-methyl-2-(2H-pyrazol-3-yl)-thiazole-5-carboxylic acid benzylamide 
• 1009378-29-3 2-(6-iodo-pyrazin-2-yl)-4-methyl-thiazole-5-carboxylic acid benzylamide 
• 1034981-25-3 N-benzyl-2-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-methylthiazole-5-carboxamide 
• 1034981-11-7 N-benzyl-2-ethynyl-4-methylthiazole-5-carboxamide 
• 1034982-00-7 N-benzyl-2-(3-benzylisoxazol-5-yl)-4-methylthiazole-5-carboxamide 
• 1105690-03-6 N-benzyl-4-methyl-2-(2-oxopyridin-1(2H)-yl)thiazole-5-carboxamide 
• 1105690-90-1 N-benzyl-2-(4-cyclopropyl-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide 
• 1105690-91-2 N-Benzyl-4-methyl-2-(4-methyl-2-oxopyridin-1(2H)-yl)thiazole-5-carboxamide 
• 1105689-98-2 N-benzyl-4-methyl-2-(2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)thiazole-5-carboxamide 
• 1105690-21-8 2-(4-benzamido-2-oxopyridin-1(2H)-yl)-N-benzyl-4-methylthiazole-5-carboxamide 
• 1105690-38-7 N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide 
• 1196065-70-9 N-benzyl-2-(3-fluorophenyl)-4-methylthiazole-5-carboxamide 
• 1105690-02-5 N-benzyl-2-(6-(benzyloxy)-2-oxoquinolin-1(2H)-yl)-4-methylthiazole-5-carboxamide 
• 1105690-01-4 N-benzyl-2-(5-(benzyloxy)-1-oxoisoquinolin-2(1H)-yl)-4-methylthiazole-5-carboxamide 

Relevant articles and documents

Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects

We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2-aminothiazole HTS hit by replacing the amide bond with a pyridinone moiety. Compound 19 demonstrated good potency against SCD1 in vitro and in vivo. The mouse liver microsomal SCD1 in vitro potency for 19 was improved by more than 240-fold compared to the original HTS hit. Furthermore, 19 demonstrated a dose-dependent reduction of plasma desaturation index with an ED50 of 6.3 mg/kg. Compound 19 demonstrated high liver to plasma and liver to eyelid exposures, indicating preferential liver distribution. The preliminary toxicology study with compound 19 did not demonstrate adverse effects related to SCD1 inhibition, suggesting a wide safety margin with respect to other known SCD1 inhibitors with wider distribution profiles.

ORGANIC COMPOUNDS

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

ORGANIC COMPOUNDS

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.